Great West Life Assurance Co. Can lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% in the first quarter, HoldingsChannel reports. The firm owned 1,819,485 shares of the biopharmaceutical company’s stock after purchasing an additional 181,393 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Gilead Sciences were worth $117,992,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Athena Capital Advisors LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $27,000. Capital Financial Planning LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth $27,000. Creative Financial Designs Inc. ADV boosted its position in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the last quarter. Claybrook Capital LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth $32,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Gilead Sciences during the first quarter worth $34,000. 78.79% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Richard James Whitley sold 9,534 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the sale, the director now directly owns 57,560 shares in the company, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. Insiders have sold 28,602 shares of company stock valued at $1,863,445 in the last quarter. 0.20% of the stock is owned by company insiders.

A number of equities analysts recently weighed in on GILD shares. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, March 7th. Mizuho restated a “buy” rating and set a $88.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 26th. Maxim Group set a $84.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Raymond James set a $90.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Finally, Citigroup restated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $79.54.

GILD stock opened at $62.25 on Friday. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $79.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The firm has a market cap of $80.75 billion, a price-to-earnings ratio of 10.12, a price-to-earnings-growth ratio of 0.77 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business earned $1.48 earnings per share. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 4.05%. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.

TRADEMARK VIOLATION WARNING: “Great West Life Assurance Co. Can Increases Holdings in Gilead Sciences, Inc. (GILD)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/great-west-life-assurance-co-can-increases-holdings-in-gilead-sciences-inc-gild/3029344.html.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.